



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Corporate Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



Date: 26 August 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: PRESS RELEASE

Dear Sir/Madam,

Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a Press Release intended for public dissemination.

Thanking you.

Yours faithfully,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer
ICSI Membership No.: A26493

Encl: a/a

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Eris Lifesciences Receives ANVISA approval for Sterile Injectable Facility

Mumbai, Aug 26, 2025: Following the Anvisa approval of an oral dose manufacturing unit, Eris Lifesciences Limited, a leading Indian branded formulations company, today announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil's national health regulatory agency. This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024.

The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, and the company expects to receive approval for the second facility soon. Both facilities are already EU-GMP and PIC/s approved and supply a range of products to several Latin American markets including Mexico, Chile, Argentina and Peru. A company spokesperson said that the Anvisa approval would enable the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market.

Commenting on the development, Mr. Amit Bakshi, CMD of Eris said, 'We take this approval as yet another endorsement of our operating and quality standards in life-saving dosage forms like injectables. This approval takes us a step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. We made major investments to initiate this transformation last year and we are glad to note that we have made significant progress in creating value from these investments with many more exciting developments expected in the quarters to come.'

About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS):

Established in 2007, Eris is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women's Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.

Eris' revenue and operating profit have grown 2.6x in the last 5 years, with FY 25 revenue of INR 2,894 cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years.

For further details please contact

Company
Eris Lifesciences Limited CIN No: L24232GJ2007PLC049867
Kruti Raval Email Id: kruti@erislifesciences.com

Safe Harbor

This document includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, allocations of funds by the Governments in the healthcare sector, increasing competition and the conditions of our customers, suppliers and the pharmaceutical industry, global and Indian demand-supply conditions finished goods prices, cyclical demand and pricing in the company's principal markets, changes in government laws and regulations, tax regimes, our provisioning policies, economic and political developments

within India and the countries within which the company conducts businesses and other factors such as litigation and labour negotiations.

Any forward-looking statement or information contained in this document speaks only as of the date of the statement.

The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events or otherwise unless it is required by Law.